Are peptidomimetics the next important step in management of advanced prostate cancer?

A team of researchers at the University of Texas Southwestern Medical Center in San Antonio are suggesting that a products known as peptidomimetics may represent an important new opportunity because of the way in which they impact androgen signaling.

The research team has just published an article entitled “Peptidomimetic targeting of critical androgen receptor–coregulator interactions in prostate cancer” in the journal Nature Communications. A media release has also been issued by the University of Texas Southwestern Medical Center.

The paper describes a specific, novel, small molecule peptidomimetic which they refer to simply as D2. The authors claim that D2 is stable, non-toxic, and efficiently taken up by prostate cancer cells. Furthermore, they report that D2 blocks androgen-induced nuclear uptake and genomic activity of the androgen receptor; is able to abrogate androgen-induced proliferation of prostate cancer cells in vitro; and inhibits tumor growth in a mouse xenograft model.

Obviously there is a great deal of work to be done before we will start to see D2 or D2-like products entering clinical trials in man, but this is another sign that researchers are getting better at identification of molecules that may be able to better control androgen signaling, and potentially convert progressive prostate cancer into a truly chronic condition.

2 Responses

  1. I forwarded this information to many prostate cancer patients, their caregivers, and physicians saying, “This looks very promising. Let’s hope that the FDA gives strong support for more rapid moving through the trial system.”

  2. Dear Chuck:

    There’s nothing the FDA can do about this until someone submits an IND to initiate clinical trials, and it will only move fast if the clinical data support such action.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: